HealthInvest Partners AB Has $5.94 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

HealthInvest Partners AB reduced its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 15.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 71,138 shares of the biopharmaceutical company’s stock after selling 13,440 shares during the quarter. Intra-Cellular Therapies comprises 2.8% of HealthInvest Partners AB’s portfolio, making the stock its 13th biggest position. HealthInvest Partners AB’s holdings in Intra-Cellular Therapies were worth $5,939,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. True Wealth Design LLC bought a new position in Intra-Cellular Therapies during the third quarter worth about $32,000. GAMMA Investing LLC raised its position in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares during the period. Capital Performance Advisors LLP bought a new position in shares of Intra-Cellular Therapies during the 3rd quarter valued at about $74,000. Venturi Wealth Management LLC acquired a new stake in Intra-Cellular Therapies during the 4th quarter worth approximately $96,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies in the third quarter valued at approximately $97,000. 92.33% of the stock is owned by institutional investors.

Intra-Cellular Therapies Stock Performance

NASDAQ ITCI opened at $128.60 on Monday. The stock has a market cap of $13.67 billion, a PE ratio of -147.81 and a beta of 0.72. The firm has a 50-day moving average of $110.27 and a 200-day moving average of $89.84. Intra-Cellular Therapies, Inc. has a 52-week low of $62.78 and a 52-week high of $128.77.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. As a group, analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Insider Buying and Selling

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

ITCI has been the topic of a number of research analyst reports. Piper Sandler restated a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. StockNews.com initiated coverage on Intra-Cellular Therapies in a research report on Monday. They issued a “hold” rating on the stock. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday. Nine research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Intra-Cellular Therapies currently has a consensus rating of “Moderate Buy” and an average price target of $103.62.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.